Eyenovia, Inc. (NASDAQ:EYEN) Major Shareholder Stuart M. Grant Purchases 33,806 Shares of Stock

Eyenovia, Inc. (NASDAQ:EYEN) major shareholder Stuart M. Grant purchased 33,806 shares of the stock in a transaction that occurred on Monday, October 25th. The stock was acquired at an average cost of $4.00 per share, with a total value of $135,224.00. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Large shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Shares of EYEN stock opened at $4.06 on Thursday. The firm has a market cap of $105.35 million, a price-to-earnings ratio of -5.07 and a beta of 2.18. The company’s 50 day moving average is $4.88 and its 200 day moving average is $4.93. The company has a quick ratio of 2.03, a current ratio of 2.03 and a debt-to-equity ratio of 0.78. Eyenovia, Inc. has a 52-week low of $3.16 and a 52-week high of $7.72.

Eyenovia (NASDAQ:EYEN) last issued its quarterly earnings data on Wednesday, August 11th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.23) by $0.04. The business had revenue of $2.00 million for the quarter. Analysts anticipate that Eyenovia, Inc. will post -0.82 EPS for the current fiscal year.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Morgan Stanley increased its holdings in Eyenovia by 246.0% in the first quarter. Morgan Stanley now owns 10,380 shares of the company’s stock valued at $53,000 after buying an additional 7,380 shares in the last quarter. Allworth Financial LP purchased a new position in Eyenovia in the second quarter valued at $38,000. BlackRock Inc. increased its holdings in Eyenovia by 23.0% in the first quarter. BlackRock Inc. now owns 59,611 shares of the company’s stock valued at $305,000 after buying an additional 11,162 shares in the last quarter. Trexquant Investment LP purchased a new position in Eyenovia in the first quarter valued at $76,000. Finally, Citadel Advisors LLC purchased a new position in Eyenovia in the first quarter valued at $91,000. Institutional investors own 8.02% of the company’s stock.

A number of research firms recently weighed in on EYEN. Zacks Investment Research lowered shares of Eyenovia from a “buy” rating to a “hold” rating in a research report on Tuesday, October 12th. Northland Securities reduced their price objective on shares of Eyenovia from $12.00 to $9.00 and set an “outperform” rating on the stock in a research report on Tuesday.

Eyenovia Company Profile

Eyenovia, Inc is a clinical stage biopharmaceutical company, which engages in the research and development of ophthalmology products. The company offers a piezo-print technology to deliver micro-doses of micro-therapeutics for the eyes. Its products include MicroProst, MicroStat, MicroTears, and MicroPine.

Recommended Story: What is a put option?

Insider Buying and Selling by Quarter for Eyenovia (NASDAQ:EYEN)

Receive News & Ratings for Eyenovia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyenovia and related companies with MarketBeat.com's FREE daily email newsletter.